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The risk of second cancers in Merkel cell carcinoma (MCC) remains uncertain since risk estimates vary worldwide. The global
MCC population is growing and there is a demand for better knowledge of prognosis of this disease. The Cochrane Database
of Systematic Reviews, MEDLINE, and EMBASE search engines were searched for the relevant literature between January 1999
and September 2014 by use of explicit search criteria. The main outcome was second malignancies associated with MCC patients
measured by standardized incidence ratios (SIRs) or other estimates of risks. Five papers fulfilled the inclusion criteria and reported
SIRs of second cancer in MCC which varied from 1.07 to 2.80. Performing meta-analysis using random effects model revealed that
there was an increased risk for second malignancies due to MCC (SIR, 1.52; 95% CI, 1.10–2.11). There was a significant increase in
risk for malignant melanoma (SIR, 3.09; 95% CI, 2.02–4.73) as compared to all common second malignancies among the studies.
Updated knowledge about risk of second malignancies in MCC will help in better assessment of the disease prognosis and will help
in optimizing the medical and surgical treatment, radiotherapy, follow-up, and surveillance procedures.

1. Introduction
Merkel cell carcinoma (MCC), a rare and aggressive neuroendocrine tumor, was first reported in 1972 as a variant
of “trabecular carcinoma of the skin” [1]. Studies based
on Survival Epidemiology and End Result Program (SEER)
have shown that estimated age-adjusted incidence rate for
MCC was as low as 0.18 to 0.41 per 100,000 population by
the year of 2006 [2]. Subsequent studies have estimated a
fourfold increase in incidence over the last two decades [3, 4].
Prognosis of this cancer is very poor because this cancer
grows rapidly and has high risk for early metastasis [5, 6].
MCC is essentially the tumor of Merkel cells, which are cells
derived from the proliferative keratinocyte layer of skin [7–
9]. Exposure to ultraviolet (UV) radiation, reactive oxygen
species, and arsenic as well as immunosuppression are some
of the known risk factors for this malignancy [10–12]. Some
studies also suspect a rare polyomavirus as the probable

causative agent [13]. This virus was demonstrated in 80%
of all MCC tumors and was successively named Merkel cell
polyomavirus (MCPyV) [14].
Currently, biopsy is the main procedure for diagnosis of MCC. Immunohistochemical staining and electron
microscopy have greatly advanced the diagnostic accuracy
[15]. MCC stains like neuron-specific enolase, synaptophysin,
chromogranin, cytokeratin 20, and CAM 5.2 have also aided
in better diagnosis of the condition [16]. Due to rarity of the
tumor, there are very few evidence based treatment protocols, and surgical excision and radiotherapy are considered
standard treatment options [17]. Though MCC is a locally
aggressive malignant tumor, there are reports of distant
metastasis and recurrences following treatment modalities
like surgery and radiotherapy [18–20].
Studies have shown associations between diagnosis of
MCC and cancers of distant organs like brain, salivary gland,
and biliary tract [21, 22]. Other malignancies like multiple

2
myeloma, chronic lymphocytic lymphoma (CLL), basal cell
carcinoma of the skin, and non-Hodgkin’s lymphoma (NHL)
have also shown positive correlation with MCC [4, 23]. In
spite of these associations, there are very few studies that
have calculated the risk for second malignancies among
MCC patients. A better knowledge of disease prognosis with
regard to second malignancies is important for optimizing
the medical and surgical management, radiotherapy, followup, and surveillance procedures for this condition. Management of second cancers associated with MCC can go
a long way with identification of pooled risks for several
common second cancers associated with the disease. The
specific aim of this meta-analysis was to gather all available
studies and provide quantitative estimates of the risks for
many second malignancies due to MCC. The objectives of
the study were (1) to perform a meta-analysis of overall
risks for second malignancies after one year of established
diagnosis of MCC; (2) to perform a metaregression analysis
to understand the influence of latitude, mean follow-up time
for second malignancies in MCC, and publication year; and
(3) to evaluate the risk for many isolated second malignancies
due to MCC.

2. Methods
2.1. Literature Searches. In order to identify studies for second
malignancies due to MCC, we searched MEDLINE, the
Cochrane Database of Systematic Reviews, and EMBASE
for studies with well-defined population cohorts. We used
MeSH terms and combination of text words such as “Merkel
cell,” “Merkel cell carcinoma,” “MCC,” “second malignancies,”
“neoplasia,” and “neuroendocrine tumors.” In the second step,
these keywords were combined using the Boolean operator
“and” and “or” with the terms “standardized incidence ratio,”
“standardized mortality ratio,” and “risk ratio.” In addition, we
searched the references lists of relevant studies to find more
published articles. We also looked for recently published
abstracts using PubMed search. We limited our search results
to include only human studies.
2.2. Inclusion and Exclusion Criteria. We included studies
that met each of the following criteria: (i) published in English
language between January 1999 and September 2014; (ii)
patients with all stages of MCC; (iii) second malignancies
in MCC cases; (iv) studies which reported risk ratio, standardized incidence ratios (SIRs), or data allowing similar
outcomes to be derived; (v) published as original papers (no
reviews, comments, letters, or editorials); (vi) studies which
reported the total number of patients with MCC and second
malignancies occurring in the cohort during follow-up; (vii)
studies which reported expected cancer incidence rates in a
matched background population and/or rates of observed-toexpected cancers with at least 90% confidence interval (CI).
Studies on only cancer mortality and referral-center studies
reviews were excluded. In case of duplicate publications, the
paper providing the longest follow-up of patients was used.
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3372 studies identified
3251 excluded after assessing titles
121 included after assessing titles

109 excluded after assessing abstract
12 included after assessing
abstracts

7 excluded after assessing full text
∙ Presented same data
∙ Insufficient data

5 studies included in the
meta-analysis

Figure 1: Flowchart for study selection.

2.3. Data Extraction and Analysis. Two authors (Muni Rubens and Venkataraghavan Ramamoorthy) reviewed all potentially relevant manuscripts to determine the studies which
met inclusion criteria. Data extracted from independent
studies were cross-checked by three reviewers (Anshul Saxena, Muni Rubens, and Hafiz Khan); disagreements were
resolved by consensus among all the authors. Extracted
data included paper characteristics (first author’s last name,
publication year, country in which the study was carried out,
and data source), study design, number of MCC patients,
mean or median age of patients, duration of follow-up, and
number of cases observed with second malignancies. We
used STATA software program (StataCorp., College Station,
TX) to calculate pooled SIRs [29]. We used 𝐼2 statistic (0%–
100%) to assess study heterogeneity for determining whether
a random or fixed effects model would be appropriate for
determining the pooled SIRs for different sets of second
malignancies [30]. Then we did metaregression analyses to
understand the influence of year of publication, mean followup years, and latitude of study location. Finally, we performed
the meta-analysis for estimation of pooled risk for all second
malignancies, as well as specific malignancies after one year
of diagnosis because most studies reported SIRs for second
malignancies at one year.

3. Results
There were five studies with a total of 3,098 cases, which
fulfilled the inclusion criteria for meta-analysis (Figure 1 and
Table 1) [24–28]. These five studies included MCC cases from
North America, Scandinavia, Middle East, Australia, and
Southern Europe. All the five studies reported nearly equal
number of observed and expected second malignancies due
to MCC. SIRs for all the five studies ranged between 1.07 (95%
CI, 0.85–1.33) and 2.80 (95% CI, 1.38–4.22). The SIRs for two
studies were almost similar, whereas for one study they were
relatively high. For the remaining two studies the SIRs were
close to one another (Table 1). The highest mean follow-up
time was 4.1 years among these five studies. Only one study
showed evidence of treatment for MCC using modalities like
surgery, radiotherapy, and chemotherapy [25].
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Table 1: Characteristics of studies included in the meta-analysis.

Study, year

Country

Data source, Number of Age at diagnosis
Mean
study period cases of MCC (𝑛 or median) follow-up

Brenner et al.,
2001 [24]

Israel

ICR
1983–1999

Howard et al.,
2006 [25]

USA

SEER
1986–2002

Koljonen et al.,
2010 [26]

Finland

FCR
1979–2006

Bzhalava et al.,
2011 [27]

Denmark
Norway
Sweden

NCR
1980–2007
1990–2007
1990–2007

Youlden et al.,
2014 [28]

Australia

QCR
1982–2010

M—35
F—32

M—756
F—560

M—53
F—119

M—314
F—442

<50 yrs.—5
50–59 yrs.—10
60–69 yrs.—11
70–79 yrs.—29
>80 yrs.—12
<60 yrs.—172
60–69 yrs.—246
>70 yrs.—888
<29 yrs.—1
30–44 yrs.—3
45–59 yrs.—14
60–74 yrs.—50
>75 yrs.—104
<29 yrs.—2
30–44 yrs.—8
45–59 yrs.—35
60–74 yrs.—181
>75 yrs.—530

M—512
F—275

75 (29–104)

Number of
second
malignancies

All malignancies Number solid
SIR (95% CI)
of cancers

3.6 years

5 (total)

2.8
(1.38–4.22)

12 (NA)

3.5 years

83 (after 1 yr.)
122 (total)

1.07
(0.85–1.33)

71 (after 1 yr.)
101 (total)

4.1 years

1 (with MCC)
33 (after ≥1 m)
34 (total)

1.69
(0.85–3.03)

30 (NA)

3.5 years

79 (after 6 m)
65 (after 1 yr.)
142 (total)

1.13
(0.89–1.44)

75 (after 6 m)
63 (after 1 yr.)

2.2 years
(median)

135 (after 2 m)
105 (after 1 yr.)
240 (total)

1.87
(1.53–2.26)

85 (after 2 m)
63 (after 1 yr.)
148 (total)

NCR: National Cancer Registries; SEER: Surveillance, Epidemiology, and End Results; FCR: Finnish Cancer Registry; NIS: National Institute of Statistics; ICR:
Israel Cancer Registry; QCR: Queensland Cancer Registry. SIR: standardized incidence ratio; CI: confidence interval.

Table 2: Risk estimates individual second malignancies occurring after one year of MCC diagnosis.
Study, year
Howard et al., 2006 [25]
Koljonen et al., 2010 [26]
Bzhalava et al., 2011 [27]
Youlden et al., 2014 [28]

Colon cancer

Breast cancer

Lung cancer

NHL

CLL

1.48
(0.76–2.58)
3.33
(0.40–12.0)
0.63
(0.26–1.53)
1.83
(1.21–2.67)

0.83
(0.30–1.81)
1.43
(0.04–7.95)
1.02
(0.42–2.45)
1.76
(0.64–3.82)

1.14
(0.61–1.95)

1.65
(0.53–3.85)

—

—

1.18
(0.02–6.56)
19.7
(0.50–109)

1.21
(0.5–2.91)
1.71
(0.82–3.14)

0.7
(0.1–4.97)
2.19
(0.60–5.61)

—
0.00
(0.00–3.83)

Malignant
melanoma
1.39
(0.28–4.07)
—
3.58
(1.49–8.6)
3.31
(1.89–5.37)

NHL: non-Hodgkin’s lymphoma; CLL: chronic lymphocytic lymphoma.

Data were pooled using random effects model because
of the significant study heterogeneity (𝐼2 = 83%). Random
effects model for estimation of risks revealed that there
was increased risk for second malignancies due to MCC
(SIR, 1.52; 95% CI, 1.10–2.11) (Figure 2). Excluding the study
reporting the highest SIR for second malignancies from the
random effects model did change the result (SIR, 1.37; 95%
CI, 1.0–1.89). On the contrary, excluding the study reporting
the lowest SIR significantly increased the risk for second
malignancies in MCC (SIR, 1.70; 95% CI, 1.17–2.47). Including
the three studies with similar SIRs also showed increased risk
for second malignancies due to MCC (SIR, 1.51; 95% CI, 1.02–
2.23).
Most studies reported the SIRs for individual malignancies. We also performed separate risk estimates for individual
second malignancies that were common in at least three

of the studies (Table 2). We pooled the SIRs for breast and
colon cancers from four studies and the SIRs for lung cancer,
non-Hodgkin’s lymphoma (NHL), chronic lymphocytic lymphoma (CLL), and malignant melanoma from three studies.
Pooled SIR for malignant melanoma was significantly higher
than the rest of the common malignancies (SIR, 3.09; 95% CI,
2.02–4.73). Colon cancer (SIR, 1.45; 95% CI, 0.89–2.36), CLL
(SIR, 2.13; 95% CI, 0.38–12.04), NHL (SIR, 1.65; 95% CI, 0.83–
3.30), lung cancer (SIR, 1.18; 95% CI, 0.79–1.74), and breast
cancer (SIR, 1.15; 95% CI, 0.69–1.91) showed increased risks
when compared to all second malignancies, though none of
them were significant (Figure 3).
We also performed analysis using random effects model
to determine the pooled risk for the combination of six
second malignancies that were common in at least three of the
studies. We obtained a total of 20 pooled SIRs. Random effects
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SIR (95% CI)

Weight (%)

Brenner et al., (2001)

2.80 (1.38, 4.22)

14.97

Howard et al., (2006)

1.07 (0.85, 1.33)

23.84

Koljonen et al., (2010)

1.69 (0.85, 3.03)

13.25

Bzhalava et al., (2011)

1.13 (0.89, 1.44)

23.43

Youlden et al., (2014)

1.87 (1.53, 2.26)

24.51

Overall (I2 = 82.8%, P = 0.000)

1.52 (1.10, 2.11)

100.00

Study (year)

Note: weights are from random effects analysis
0.237

1

4.22

Figure 2: MCC and the risk of second cancer. Squares indicate the odds ratios for the individual studies; horizontal lines indicate the 95%
confidence interval. The size of the data marker corresponds to the relative weight assigned in the pooled analysis using the random effects
model. Diamond indicates the pooled odds ratios with 95% confidence interval.

model estimate revealed that there was a significant increase
in risk for these six second malignancies when compared to
the grand total of all malignancies (SIR, 1.52; 95% CI, 1.20–
1.93). The risk did not increase from 52% for these common
six malignancies when compared to all second malignancies.
Metaregression analyses to understand the effects of
mean follow-up years, geographic location (latitude), and
publication year on the risk for all second malignancies due
to MCC showed that, after allowing for additive residual
heterogeneity, there was no significant association between
geographic location, mean years of follow-up, and publication year and second malignancies. However, the SIR and
absolute latitude showed negative relationship; that is, the
higher the absolute latitude, the lower the SIR, and hence
the lower the risk of second cancers (𝑃 > 0.05). The year of
publication (𝑃 > 0.05) and mean follow-up years (𝑃 > 0.50)
showed positive relationship; that is, the higher the mean
follow-up period or the year of publication, the higher the
chances of reporting a second cancer.

4. Discussion
This could be the first meta-analysis of second malignancies
in MCC. We have restricted our search to include population
based studies because such studies are the best fit for overall
analysis of associated risks for many diseases. Many of the
individual studies assert that being diagnosed with MCC
poses an increased risk of being diagnosed with second
primary cancer. Our results are consistent with previous
reports that people with MCC are at a significantly higher risk
for developing second malignancies when compared to the
general population, and such risk would be present 1 to 5 years

after having MCC as primary cancer. Our study asserts that
patients who are diagnosed with MCC are 52% more likely
to develop second cancers after one-year period as compared
to the general population. The risk of developing malignant
melanoma was two times more likely in patients with MCC
as compared to other common malignancies. Thus we derived
that, after diagnosis of MCC, there is a need to emphasize on
the screening and prevention of second cancers along with
the treatment of MCC.
Studies that were conducted before 10 years showed
increased SIRs for second malignancies due to MCC, whereas
studies that are recently conducted show decreased risk
for second malignancies. This trend could be ascribed to
better diagnostic and therapeutic procedures which in turn
could have decreased the risk for second malignancies [31].
Assessment for the association between treatment exposure
and risk for second malignancies was not performed as only
one study reported exposure to treatment [25].
Our study faces some limitations such as the methodology of studies which was not assessed considering the
shortcomings of quality scoring in observational studies,
failure to include studies in languages other than English,
large heterogeneity among individual studies, and extremely
large duration of observed period in individual studies (1979–
2010) [32–34]. The long number of years of study duration
was a limitation because many advances have happened in
both diagnostic procedures as well as therapeutic regimens
for many different types of cancers during these years.
Another impediment was that many specific cancers were
grouped differently in individual papers thereby making
comparability difficult. In addition, other factors that acted
against our meta-analysis include small number of studies,
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Study (year)
Lung
Howard et al., (2006)
Bzhalava et al., (2011)
Youlden et al., (2014)
Subtotal (I2 = 0.0%,
P = 0.989)
Colon
Howard et al., (2006)
Koljonen et al., (2010)
Bzhalava et al., (2011)
Youlden et al., (2014)
Subtotal (I2 = 44.8%,
P = 0.142)
Breast
Howard et al., (2006)
Koljonen et al., (2010)
Bzhalava et al., (2011)
Youlden et al., (2014)
Subtotal (I2 = 0.0%,
P = 0.688)
CLL
Howard et al., (2006)
Koljonen et al., (2011)
Youlden et al., (2014)
Subtotal (I2 = 54.9%,
P = 0.109)
NHL
Howard et al., (2006)
Bzhalava et al., (2011)
Youlden et al., (2014)
Subtotal (I2 = 0.0%,
P = 0.610)
MM
Howard et al., (2006)
Bzhalava et al., (2011)
Youlden et al., (2014)
Subtotal (I2 = 0.0%,
P = 0.462)
Overall (I2 = 31.8%,
P = 0.086)
Note: weights are from
random effects analysis

0.015

0.085

1

5

25

SIR (95% CI)

Weight (%)

1.14 (0.61, 1.95)
1.21 (0.50, 2.91)
1.21 (0.82, 3.14)
1.18 (0.79, 1.74)

8.66
5.18
7.38
21.22

1.48 (0.76, 2.58)
3.33 (0.40, 12.00)
0.63 (0.26, 1.53)
1.83 (1.21, 2.67)
1.45 (0.89, 2.36)

8.21
1.76
5.14
11.99
27.09

0.83 (0.30, 1.81)
1.43 (0.04, 7.95)
1.02 (0.42, 2.45)
1.76 (0.64, 3.82)
1.15 (0.70, 1.91)

5.03
0.77
5.17
5.08
16.06

1.18 (0.02, 6.56)
19.70 (0.50, 109.00)
1.00 (1.00, 3.83)
2.13 (0.38, 12.04)

0.65
0.75
7.38
8.78

1.65 (0.53, 3.85)
0.70 (0.10, 4.97)
2.19 (0.60, 5.61)
1.65 (0.83, 3.30)

4.35
1.37
3.61
9.33

1.39 (0.28, 4.07)
3.58 (1.49, 8.60)
3.31 (1.89, 5.37)
3.09 (2.02, 4.73)

2.68
5.22
9.62
17.52

1.52 (1.20, 1.93)

100.00

115

Figure 3: Risk of second cancer after one year of MCC diagnosis. Squares indicate the odds ratios for the individual studies; horizontal lines
indicate the 95% confidence interval. The size of the data marker corresponds to the relative weight assigned in the pooled analysis using
the random effects model. Diamond indicates the pooled odds ratios with 95% confidence interval. NHL: non-Hodgkin’s lymphoma; CLL:
chronic lymphocytic lymphoma; MM: malignant melanoma.

restricted details in the selected studies, and lack of comparability factors due to rarity of the disease itself. There were
wide variations in the risk estimates in individual studies
as reflected in the differences between SIRs for total second
malignancies due to MCC. This could be due to selection
biases and other limitations associated with individual studies
themselves.
The strengths of our study include use of standardized
tools to retrieve studies as well as standard meta-analysis
procedures to pool data. Our studies cover wide geographical

areas from Asia to Middle East, Australia, North America,
and Scandinavia. Incidentally, we observed that latitude
played a role in increasing the risk for second malignancies
due to MCC. However, this finding was not significant. There
should be further studies on the relationship between exposure to UV radiations and risk for having second malignancy
due to MCC.
Several explanations can be given for the increase for
second malignancies in MCC that we observed. MCC is an
extremely aggressive cancer with 5-year survival rates ranging
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from 68%, 52%, and 17% for local disease, regional disease,
and distant metastasis, respectively [2]. Many of the second
malignancies associated with MCC are slow growing tumors
and therefore are masked by the effects of MCC itself.

5. Conclusion
Our results demonstrate that there is overall increased risk
for second malignancies one year after the diagnosis of
MCC. Malignant melanoma alone had two times more risk
when compared to other second cancers after one year of
diagnosis of MCC. The complexity of MCC involves several
factors like genetic susceptibility, environmental factors, and
biological factors, thereby warranting further studies with
greater number of variables.
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